Cardiology Xagena
Subcutaneous administration of Inclisiran, a small-interfering RNA ( siRNA ) directed against proprotein convertase subtilisin/kexin type 9 ( PCSK9 ), was associated with substantial and sustained low ...
Edoxaban ( Lixiana ) in combination with a P2Y12 inhibitor is noninferior to standard triple therapy for preventing bleeding in patients with atrial fibrillation after coronary stenting. The results ...
At the European Society of Cardiology Congress 2019, researchers from Brigham and Women's Hospital and Greater Paris University Hospitals - AP-HP/Université de Paris, have presented the results from T ...
A large Cleveland Clinic study has shown that weight-loss surgery performed in patients with type 2 diabetes and obesity is associated with a lower risk of death and major adverse cardiovascular event ...
Low-dose Aspirin ( Acetylsalicylic acid ) does not prolong disability-free survival of healthy people over 70, even in those at the highest risk of cardiovascular disease. The results of the ASPREE ...
Detailed results from the landmark phase III DAPA-HF trial, presented at the ESC Congress 2019, have shown that Dapagliflozin ( Farxiga ), on top of standard of care, has reduced both the incidence of ...
The results from the global phase III PARAGON-HF study, investigating the safety and efficacy of Sacubitril / Valsartan ( Entresto ) versus the active comparator Valsartan in HFpEF ( heart failure wit ...
Chronic kidney disease is associated with an increased risk of both bleeding and ischemic cardiovascular events. The purpose of this study was to determine the balance of risks and benefits from th ...
Patients with chronic coronary artery disease ( CAD ) or peripheral artery disease ( PAD ) and history of heart failure ( HF ) are at high risk for major adverse cardiovascular events ( MACE ). Re ...
Patients with left-sided heart failure who get implanted devices to improve the pumping of their hearts may be more likely to develop heart failure on the opposite side of their hearts if they are pre ...
Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of Sacubitril - Valsartan ( Entresto ) therapy is safe and eff ...
EMPRISE is a study program on the effectiveness, safety and healthcare utilization of Empagliflozin ( Jardiance ), a SGLT2 inhibitor ( SGLT2i ), in routine care across a spectrum of cardiovascular bas ...
The results from an independent retrospective comparative study, published in the American Journal of Medicine, have shown that Dabigatran was associated with a more favourable benefit-harm profile th ...
Nonvitamin K antagonist oral anticoagulants ( NOACs ) are alternatives to Warfarin ( Coumadin ) in patients with nonvalvular atrial fibrillation. Randomized trials compared NOACs with Warfarin, but ...
The ODYSSEY OUTCOMES ( Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab ) trial compared Alirocumab ( Praluent ) with placebo, added to high-inte ...
